News for Selecta Biosciences, Inc. (SELB)

SAN FRANCISCO and VANCOUVER, British Columbia, July 01, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ('Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Brad Dahms as Chief Financial Officer.

A range of new options have been listed for trading beginning April 16th, featuring notable companies and ETFs. Among these, Avalo Therapeutics (AVTX) stands ou

**media[579911]**

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care

Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report

Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout

PHILADELPHIA, Jan. 18, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Cartesian Therapeutics, Inc. , formerly known as Selecta Biosciences, Inc. , on behalf of the...

BALA CYNWYD, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to...

Reinet Investments SCA / Key word: Half Year Results CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE SIX-MONTH PERIOD ENDED 30 SEPTEMBER 2023 15-Nov-2023 / 07:00 CET/CEST Release of an...

Selecta Biosciences merges with Cartesian Therapeutics in all-stock deal

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Selecta Biosciences, Inc. (NASDAQ: SELB) (“Selecta”)...

INDP | Complete Indaptus Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Abbott Cooper PLLC Announces Investigation into Selecta Biosciences, Inc....

/PRNewswire/ -- The

Source: Yun Zhong March 28, 2023 (Investorideas.com Newswire) Despite a competitor already on the market, the commercial opportunity for this particular treatm...

Seer went public in December 2020, raising approximately $175 million in a U.S. IPO. Click here to see our take on SEER stock.

Reinet Investments SCA / Key word: Quarter Results MANAGEMENT STATEMENT FOR THE THIRD QUARTER ENDED 31 DECEMBER 2022 24-Jan-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to... | January 24, 2023

Visiongain has published a new report entitled the Nanotechnology in Drug Delivery 2022-2032. It includes profiles of Nanotechnology in Drug Delivery...

Read Reviewing Ginkgo Bioworks (NYSE:DNA) & Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) at ETF Daily News